Myelodysplastic Syndromes

Classification and Cytopathology of Myelodysplastic Syndromes.- The Classification of Myelodysplastic Syndromes.- Discussion.- Classification of Myelodysplastic Syndromes in Clinical Practice: Frequency of Subtypes.- Pathogenesis of Anaemia in the Myelodysplastic Syndrome.- Immunological Abnormalities in the Myelodysplastic Syndrome.- Pediatric Experiences in Myelodysplastic Syndrome.- Myelodysplastic Syndromes in Childhood: Description of 11 Cases.- The Value of Cytochemical Investigations in the Diagnosis of the Myelodysplastic Syndromes.- Enzyme Cytochemical Studies in Myelodysplastic Syndromes.- Immunological Phenotyping of Blood and Bone Marrow Cells From Patients with Myelodysplastic Syndromes.- Bone Marrow Biopsy in RAEB and RAEB-t Myelodysplastic Syndromes.- Discussion of Poster Session I.- Cyto- and Histopathology of Myelodysplastic Syndrome.- Maturation Pattern and Evolution of Leukemia in the Myelodysplastic Syndrome.- Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia.- The Prognostic Value of Abnormal Localization of Immature Precursors in the Myelodysplastic Syndromes.- Bone Marrow Histology in Myelodysplastic Syndromes: An Update.- Evolution of Myelodysplastic Syndromes.- Conversion of Myelodysplastic Subtypes to Acute Leukemia: A Follow-Up Study.- Primary Myelodysplastic Syndromes and Chronic Myelofibrosis.- Myelodysplastic Syndrome with Myelofibrosis: A Report of Seven Cases.- Chronic Myelomonocytic Leukemia.- Chronic Myelomonocytic Leukaemia and Atypical Chronic Myeloid Leukaemia.- Chronic Myelomonocytic Leukemia with Lymphadenopathy.- Generalized Lymphadenopathy in Juvenile Chronic Myelomonocytic Leukemia Is Due to Lymph Node Infiltration with Myelomonocytic Cells and Immature T Cells.- Impaired Monocyte/Macrophage Differentiation in the Myelodysplastic Syndromes.- Discussion of Poster Session II.- Cytogenetic Anomalies and Molecular Biology of Myelodysplastic Syndromes.- Myelodysplastic Syndromes: Cytogenetic Anomalies and Their Clinical Significance.- Genetic Consequences of Chromosomal Abnormalities in the Myelodysplastic Syndromes.- ras Mutations in the Myelodysplastic Syndromes.- Study of the Rearrangement of Proto-oncogene MET in 88 Cases of Myelodysplastic Syndromes.- In Vitro-Culture Studies in Myelodysplastic Syndromes.- ras Oncogenes in Myelodysplastic Syndromes.- Growth Factors in Myelodysplastic Syndromes.- In Vitro Granulopoiesis in Myelodysplastic Syndromes According to the FAB Classification.- Therapy of Myelodysplastic Syndromes: Supportive Care and Chemotherapy.- Therapeutic Implications of Understanding Pathogenesis: Clinical Relevance of Prognostic Factors.- Supportive Therapy and Bone Marrow Transplantation in MDS.- Retinoic Acid Therapy in the Myelodysplastic Syndrome.- Phase III Evaluation of Low-Dose Cytosine Arabinoside Versus Supportive Care in the Treatment of Adults With Myelodysplastic Syndrome: An Intergroup Study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group — Preliminary Results.- Intensive Chemotherapy in Myelodysplastic Syndromes.- Therapeutic Effects of Low-Dose Cytosine Arabinoside Without or With 1;25-Dihydroxyvitamin D3 in Myelodysplastic Syndromes and in Elderly Acute Nonlymphocytic Leukemia.- Low-Dose Cytosine Arabinoside Regimen Adapted to the FAB Classifications of Myelodysplastic Syndromes: Is it Superior to Uniform Treatment for all Types of MDS?.- Results of Low-Dose Cytosine Arabinoside and Agressive Chemotherapy in Patients with Advanced Myelodysplastic Syndromes.- Aggressive Chemotherapy in Adult Primary Myelodysplastic Syndromes: A Report on 29 Cases.- Therapy of Myelodysplastic Syndromes: Biological Response Modifiers and Growth Factors.- Recombitant ?2b-Interferon in the Management of Myelodysplastic Syndromes.- A Phase II Clinical Trial of Recombinant Interferon-? on Myelodysplastic Syndromes.- Treatment of Patients with Myelodysplastic Syndromes with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor: A Phase I/II Trial.- Combined Treatment Modality with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor and Low-Dose Cytosine Arabinoside in Patients with Myelodysplastic Syndromes.- GM-CSF Combined with Low-Dose Cytosine Arabinoside: A Trial Proposed for High-Risk Myelodysplastic Syndromes and Results of a Dose-Finding Study.- Discussion of Poster Session III.